Exploring the Cost Effectiveness of Shared Decision Making for Choosing between Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis in the Netherlands: A State Transition Model

BACKGROUND: Up to 31% of patients with relapsing-remitting multiple sclerosis (RRMS) discontinue treatment with disease-modifying drug (DMD) within the first year, and of the patients who do continue, about 40% are nonadherent. Shared decision making may decrease nonadherence and discontinuation rat...

Descripción completa

Detalles Bibliográficos
Autores principales: Kremer, Ingrid E. H., Hiligsmann, Mickael, Carlson, Josh, Zimmermann, Marita, Jongen, Peter J., Evers, Silvia M. A. A., Petersohn, Svenja, Pouwels, Xavier G. L. V., Bansback, Nick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672783/
https://www.ncbi.nlm.nih.gov/pubmed/33174513
http://dx.doi.org/10.1177/0272989X20961091

Ejemplares similares

Ejemplares similares